** Shares of Inovio Pharmaceuticals INO.O down 7% premarket to $2 after $25 mln follow-on prices

** Plymouth Meeting, Pennsylvania-based biotech says it sold ~13.2 mln shares at $1.90, a 11.6% discount to stock's last close

** Piper Sandler sole bookrunner for offering

** After the bell Mon, INO reported Q3 results and reiterated it's seeking accelerated approval from U.S. FDA for lead candidate INO-3017 after completing rolling biologics license application submission

** INO-3107 is a potential treatment for recurrent respiratory papillomatosis , a disease in which benign (noncancerous) tumors called papillomas grow in the air passages leading from the nose and mouth into the lungs

** Co has ~53.1 mln shares outstanding

** INO shares on Mon edged up 1.4%. up 17.5% YTD

** 4 of 6 analysts rate the stock "strong buy" or "buy", 2 rate "hold"; median PT is $7.50, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))